Role of γ-glutamyl transferase levels in prediction of high cardiovascular risk among patients with non-alcoholic fatty liver disease

Indian Journal of Medical Research

Volumn 143, Issue JANUARY, 2016, Pages 30-36

  Kasapoglu, Benan ^a   Turkay, Cansel ^a   Yalcın, Kadir Serkan ^a   Carlioglu, Ayse ^a   Koktener, Aslı ^a  

^a TURGUT OZAL UNIVERSITY   (Turkey)

Author keywords

Bmi; Cardiovascular disease risk score; Framingham; Gamma glutamyl transferase; Non alcoholic fatty liver disease; Non obese

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROTROPIN; URIC ACID; LIPID;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; PATHOLOGY;

ADULT; AGED; BIOMARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIPIDS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84960965212     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-5916.178585     Document Type: Article

References (31)

1. Mishra A, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. J Clin Exp Hepatol 2012; 2:135-44.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-31.
3. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129:113-21.
4. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012; 91:319-27.
5. Lee YJ, Shim JY, Moon BS, Shin YH, Jung DH, Lee JH, et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012; 57:196-203.
6. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191:235-40.
7. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 (Suppl 1):S11-6.
8. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013; 230:258-67.
9. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 2009; 302:2345-52.
10. World Health Organization and International Diabetes Fedaration. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF Consultation. Geneva, Switzerland: WHO; 2006. p. 1-3.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9.
12. Framingham Heart Study: General cardiovascular disease (10 years risk): risk score calculators. Available from: http://www.framinghamheartstudy.org/risk-functions/cardiovascular-disease/10-year-risk.php, accessed on January 10, 2016.
13. Murphy TP, Dhangana R, Pencina MJ, Zafar AM, D’Agostino RB. Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment. Atherosclerosis 2011; 216:452-7.
14. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986; 292:13-5.
15. Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012; 32:945-50.
16. Hamaguchi M, Kojima T, Takeda N, Sarui H, Kawahito Y, Yoshida N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13:1579-84.
17. Acıkel M, Sunay S, Koplay M, Gundoğdu F, Karakelleoğlu Ş. Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis, and obesity in patients undergoing coronary angiography. Anadolu Kardiyol Derg 2009; 9:273-9.
18. Tarantino G, Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol 2013; 19:3375-84.
19. Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol 2013; 19:802-12.
20. Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, et al. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 2006; 44:190-6.
21. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995; 142:699-708.
22. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma glutamyl transferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005; 112:2130-7.
23. Strasak AM, Kelleher CC, Klenk J, Brant LJ, Ruttmann E, Rapp K, et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults. Arterioscler Thromb Vasc Biol 2008; 28:1857-65.
24. Kasapoglu B, Turkay C, Bayram Y, Koca C. Role of GGT in diagnosis of metabolic syndrome: a clinic-based cross-sectional survey. Indian J Med Res 2010; 132:56-61.
25. Tarantino G, Finelli C, Colao A, Capone D, Tarantino M, Grimaldi E, et al. Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase? J Transl Med 2012; 10:50.
26. Matsha TE, Macharia M, Yako YY, Erasmus RT, Hassan MS, Kengne AP. Gamma-glutamyl transferase, insulin resistance and cardiometabolic risk profile in a middle-aged African population. Eur J Prev Cardiol 2013; 21:1541-8.
27. Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, et al. Serum ferritin levels lack diagnostic accuracy for liver-fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12:1163-9.
28. Zhang JX, Zhang YP, Wu QN, Chen B. Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-L1 adipocytes. Endocrine 2014; 48:135-42.
29. Yamada T, Suzuki S, Fukatsu M, Wada T, Yoshida T, Joh T. Elevated serum uric acid is an independent risk factor for nonalcoholic fatty liver disease in Japanese undergoing a health check-up. Acta Gastroenterol Belg 2010; 73:12-7.
30. Abdelmalek MF, Lazo M, Horska A, Bonekamp S, Lipkin EW, Balasubramanyam A, et al. Fatty Liver Subgroup of Look AHEAD Research Group. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology 2012; 56:952-60.
31. Eichler K, Puhan MA, Steurer J, Bachmann LM. Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J 2007; 153:722-31, 731.e1-8.